{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:56:46Z","timestamp":1790816206140,"version":"4.1.0"},"posted":{"date-parts":[[2026,6,19]]},"group-title":"In Review","reference-count":53,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,6,8]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Background:\n Parkinson\u2019s disease (PD) is characterized by progressive degeneration of\n                  <italic>substantia nigra pars compacta<\/italic>\n                  (SNc) dopaminergic (DA) neurons and the development of motor and non-motor impairments. Mitochondrial dysfunction, exacerbated by aging and environmental exposures, is a central contributor to PD pathogenesis. Nicotinamide riboside (NR), a dietary precursor of nicotinamide adenine dinucleotide (NAD\u207a), enhances cellular bioenergetics and mitochondrial health, yet its translational potential for PD remains insufficiently defined.\nMethods:\n We used a \u201cdouble-hit\u201d PD mouse model combining A53T \u03b1-synuclein overexpression in SNc DA neurons with chronic dietary benomyl exposure. Mice received continuous NR supplementation in drinking water. Motor behavior was monitored longitudinally using open-field and rotarod assays. Striatal dopamine dynamics were quantified using genetically encoded fluorescent dopamine sensors to measure tonic and optogenetically evoked dopamine release. In vivo ATP\/ADP ratios were measured in DA neurons and striatal spiny projection neurons (SPNs) using fiber photometry of the ratiometric sensor PercevalHR.\nResults:\n Chronic NR supplementation markedly improved motor performance in double-hit PD mice, despite failing to prevent SNc DA neuron degeneration. NR robustly increased both tonic and stimulus-evoked striatal dopamine release in control and PD mice. Additionally, NR elevated ATP\/ADP ratios across multiple neuronal populations, indicating enhanced mitochondrial energetic capacity.\nConclusions:\n NR supplementation enhances DA neurotransmission and mitochondrial bioenergetics in vivo, conferring functional benefits that occur independently of DA neuron survival. These findings identify metabolic augmentation via NR as a promising adjunctive strategy for mitigating PD-related functional deficits.\n                <\/p>","DOI":"10.21203\/rs.3.rs-9970859\/v1","type":"posted-content","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:01:36Z","timestamp":1781884896000},"source":"Crossref","is-referenced-by-count":1,"title":["Nicotinamide Riboside Enhances Mitochondrial Bioenergetics and Dopaminergic Signaling Independent of Neuron Survival in a Double-Hit Parkinson\u2019s Model"],"prefix":"10.21203","author":[{"given":"Sukanya","family":"Saha","sequence":"first","affiliation":[{"name":"National Institute of Environmental Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengbo","family":"Meng","sequence":"additional","affiliation":[{"name":"National Institute of Environmental Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Dong","sequence":"additional","affiliation":[{"name":"National Institute on Aging"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingheng","family":"Zhou","sequence":"additional","affiliation":[{"name":"National Institute of Environmental Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny","family":"Wang","sequence":"additional","affiliation":[{"name":"National Institute of Environmental Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Papaneri","sequence":"additional","affiliation":[{"name":"National Institute of Environmental Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Sun","sequence":"additional","affiliation":[{"name":"National Institute on Aging"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaibin","family":"Cai","sequence":"additional","affiliation":[{"name":"National Institute on Aging"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohong","family":"Cui","sequence":"additional","affiliation":[{"name":"National Institute of Environmental Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson's disease","volume":"397","author":"Bloem BR","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C: Parkinson's disease. Lancet 2021, 397:2284\u20132303.","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrn.2016.178","article-title":"Selective neuronal vulnerability in Parkinson disease","volume":"18","author":"Surmeier DJ","year":"2017","unstructured":"Surmeier DJ, Obeso JA, Halliday GM: Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci 2017, 18:101\u2013113.","journal-title":"Nat Rev Neurosci"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Collaborators GBDN","year":"2019","unstructured":"Collaborators GBDN: Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019, 18:459\u2013480.","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","article-title":"Progress towards therapies for disease modification in Parkinson's disease","volume":"20","author":"Vijiaratnam N","year":"2021","unstructured":"Vijiaratnam N, Simuni T, Bandmann O, Morris HR, Foltynie T: Progress towards therapies for disease modification in Parkinson's disease. Lancet Neurol 2021, 20:559\u2013572.","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia LV","year":"2015","unstructured":"Kalia LV, Lang AE: Parkinson's disease. Lancet 2015, 386:896\u2013912.","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pharmthera.2019.01.001","article-title":"Environmental neurotoxicant-induced dopaminergic neurodegeneration: a potential link to impaired neuroinflammatory mechanisms","volume":"197","author":"Kanthasamy A","year":"2019","unstructured":"Kanthasamy A, Jin H, Charli A, Vellareddy A, Kanthasamy A: Environmental neurotoxicant-induced dopaminergic neurodegeneration: a potential link to impaired neuroinflammatory mechanisms. Pharmacol Ther 2019, 197:61\u201382.","journal-title":"Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.molbrainres.2004.11.007","article-title":"Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures","volume":"134","author":"Testa CM","year":"2005","unstructured":"Testa CM, Sherer TB, Greenamyre JT: Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res Mol Brain Res 2005, 134:109\u2013118.","journal-title":"Brain Res Mol Brain Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/NRE-210040","article-title":"\"Going Backward\": Effects of age and fatigue on posterior-directed falls in Parkinson disease","volume":"49","author":"Papa EV","year":"2021","unstructured":"Papa EV, Patterson RM, Bugnariu N: \"Going Backward\": Effects of age and fatigue on posterior-directed falls in Parkinson disease. Neurorehabilitation 2021, 49:151\u2013159.","journal-title":"Neurorehabilitation"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41540-020-00150-w","article-title":"ROS networks: designs, aging, Parkinson's disease and precision therapies","volume":"6","author":"Sharma ANK","year":"2020","unstructured":"A NK, Sharma RP, Colangelo AM, Ignatenko A, Martorana F, Jennen D, Briede JJ, Brady N, Barberis M, Mondeel T, et al: ROS networks: designs, aging, Parkinson's disease and precision therapies. NPJ Syst Biol Appl 2020, 6:34.","journal-title":"NPJ Syst Biol Appl"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jad.2021.01.056","article-title":"Treatment response and age of onset as risk indicators for parkinson disease in patients with major depressive disorder: A nationwide longitudinal study","volume":"283","author":"Chan YE","year":"2021","unstructured":"Chan YE, Chen MH, Bai YM, Li CT, Chen TJ, Su TP: Treatment response and age of onset as risk indicators for parkinson disease in patients with major depressive disorder: A nationwide longitudinal study. J Affect Disord 2021, 283:329\u2013334.","journal-title":"J Affect Disord"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1136\/jnnp-2020-323646","article-title":"Parkinson's disease determinants, prediction and gene-environment interactions in the UK Biobank","volume":"91","author":"Jacobs BM","year":"2020","unstructured":"Jacobs BM, Belete D, Bestwick J, Blauwendraat C, Bandres-Ciga S, Heilbron K, Dobson R, Nalls MA, Singleton A, Hardy J, et al: Parkinson's disease determinants, prediction and gene-environment interactions in the UK Biobank. J Neurol Neurosurg Psychiatry 2020, 91:1046\u20131054.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"102070","DOI":"10.1016\/j.pneurobio.2021.102070","article-title":"alpha-synuclein aggregates induce c-Abl activation and dopaminergic neuronal loss by a feed-forward redox stress mechanism","volume":"202","author":"Ghosh S","year":"2021","unstructured":"Ghosh S, Won SJ, Wang J, Fong R, Butler NJM, Moss A, Wong C, Pan J, Sanchez J, Huynh A, et al: alpha-synuclein aggregates induce c-Abl activation and dopaminergic neuronal loss by a feed-forward redox stress mechanism. Prog Neurobiol 2021, 202:102070.","journal-title":"Prog Neurobiol"},{"key":"ref13","author":"Zaltieri M","year":"2015","unstructured":"Zaltieri M, Longhena F, Pizzi M, Missale C, Spano P, Bellucci A: Mitochondrial Dysfunction and alpha-Synuclein Synaptic Pathology in Parkinson's Disease: Who's on First? Parkinsons Dis 2015, 2015:108029."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi P","year":"2023","unstructured":"Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V: Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 2023, 14:176.","journal-title":"Cell Death Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos MH","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al: Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045\u20132047.","journal-title":"Science"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"S63-64","DOI":"10.1002\/ana.410440710","article-title":"Autosomal dominant Parkinson's disease and alpha-synuclein","volume":"44","author":"Polymeropoulos MH","year":"1998","unstructured":"Polymeropoulos MH: Autosomal dominant Parkinson's disease and alpha-synuclein. Ann Neurol 1998, 44:S63-64.","journal-title":"Ann Neurol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"10814","DOI":"10.1074\/jbc.M110.132514","article-title":"Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy","volume":"286","author":"Choubey V","year":"2011","unstructured":"Choubey V, Safiulina D, Vaarmann A, Cagalinec M, Wareski P, Kuum M, Zharkovsky A, Kaasik A: Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem 2011, 286:10814\u201310824.","journal-title":"J Biol Chem"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of alpha-synuclein: from structure and toxicity to therapeutic target","volume":"14","author":"Lashuel HA","year":"2013","unstructured":"Lashuel HA, Overk CR, Oueslati A, Masliah E: The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 2013, 14:38\u201348.","journal-title":"Nat Rev Neurosci"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"110186","DOI":"10.1016\/j.envres.2020.110186","article-title":"Pesticide use and incident Parkinson's disease in a cohort of farmers and their spouses","volume":"191","author":"Shrestha S","year":"2020","unstructured":"Shrestha S, Parks CG, Umbach DM, Richards-Barber M, Hofmann JN, Chen H, Blair A, Beane Freeman LE, Sandler DP: Pesticide use and incident Parkinson's disease in a cohort of farmers and their spouses. Environ Res 2020, 191:110186.","journal-title":"Environ Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"101966","DOI":"10.1016\/j.jchemneu.2021.101966","article-title":"Pesticides and Parkinson's disease: Current and future perspective","volume":"115","author":"Islam MS","year":"2021","unstructured":"Islam MS, Azim F, Saju H, Zargaran A, Shirzad M, Kamal M, Fatema K, Rehman S, Azad MAM, Ebrahimi-Barough S: Pesticides and Parkinson's disease: Current and future perspective. J Chem Neuroanat 2021, 115:101966.","journal-title":"J Chem Neuroanat"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1073\/pnas.1220399110","article-title":"Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease","volume":"110","author":"Fitzmaurice AG","year":"2013","unstructured":"Fitzmaurice AG, Rhodes SL, Lulla A, Murphy NP, Lam HA, O'Donnell KC, Barnhill L, Casida JE, Cockburn M, Sagasti A, et al: Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proc Natl Acad Sci U S A 2013, 110:636\u2013641.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e31522","DOI":"10.1371\/journal.pone.0031522","article-title":"Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease","volume":"7","author":"Wey MC","year":"2012","unstructured":"Wey MC, Fernandez E, Martinez PA, Sullivan P, Goldstein DS, Strong R: Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease. PloS one 2012, 7:e31522.","journal-title":"PloS one"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/tx980002l","article-title":"Mechanism for benomyl action as a mitochondrial aldehyde dehydrogenase inhibitor in mice","volume":"11","author":"Staub RE","year":"1998","unstructured":"Staub RE, Quistad GB, Casida JE: Mechanism for benomyl action as a mitochondrial aldehyde dehydrogenase inhibitor in mice. Chem Res Toxicol 1998, 11:535\u2013543.","journal-title":"Chem Res Toxicol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1021\/tx5002223","article-title":"Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease","volume":"27","author":"Casida JE","year":"2014","unstructured":"Casida JE, Ford B, Jinsmaa Y, Sullivan P, Cooney A, Goldstein DS: Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease. Chem Res Toxicol 2014, 27:1359\u20131361.","journal-title":"Chem Res Toxicol"},{"key":"ref25","first-page":"12","article-title":"Nicotinamide Riboside-The Current State of Research and Therapeutic Uses","author":"Mehmel M","year":"2020","unstructured":"Mehmel M, Jovanovic N, Spitz U: Nicotinamide Riboside-The Current State of Research and Therapeutic Uses. Nutrients 2020, 12.","journal-title":"Nutrients"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e42357","DOI":"10.1371\/journal.pone.0042357","article-title":"Age-associated changes in oxidative stress and NAD+ metabolism in human tissue","volume":"7","author":"Massudi H","year":"2012","unstructured":"Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ: Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One 2012, 7:e42357.","journal-title":"PLoS One"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tcb.2014.04.002","article-title":"NAD\u2009+\u2009and sirtuins in aging and disease","volume":"24","author":"Imai S","year":"2014","unstructured":"Imai S, Guarente L: NAD\u2009+\u2009and sirtuins in aging and disease. Trends Cell Biol 2014, 24:464\u2013471.","journal-title":"Trends Cell Biol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aac4854","article-title":"NAD(+) in aging, metabolism, and neurodegeneration","volume":"350","author":"Verdin E","year":"2015","unstructured":"Verdin E: NAD(+) in aging, metabolism, and neurodegeneration. Science 2015, 350:1208\u20131213.","journal-title":"Science"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/HNP.0000000000000461","article-title":"Nicotinamide Adenine Dinucleotide (NAD+) Biosynthesis in the Regulation of Metabolism, Aging, and Neurodegeneration","volume":"35","author":"Ross SM","year":"2021","unstructured":"Ross SM: Nicotinamide Adenine Dinucleotide (NAD+) Biosynthesis in the Regulation of Metabolism, Aging, and Neurodegeneration. Holist Nurs Pract 2021, 35:230\u2013232.","journal-title":"Holist Nurs Pract"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1038\/emm.2017.74","article-title":"Upregulation of mitochondrial NAD(+) levels impairs the clonogenicity of SSEA1(+) glioblastoma tumor-initiating cells","volume":"49","author":"Son MJ","year":"2017","unstructured":"Son MJ, Ryu JS, Kim JY, Kwon Y, Chung KS, Mun SJ, Cho YS: Upregulation of mitochondrial NAD(+) levels impairs the clonogenicity of SSEA1(+) glioblastoma tumor-initiating cells. Exp Mol Med 2017, 49:e344.","journal-title":"Exp Mol Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"16017","DOI":"10.1038\/npjamd.2016.17","article-title":"It takes two to tango: NAD(+) and sirtuins in aging\/longevity control","volume":"2","author":"Imai SI","year":"2016","unstructured":"Imai SI, Guarente L: It takes two to tango: NAD(+) and sirtuins in aging\/longevity control. NPJ Aging Mech Dis 2016, 2:16017.","journal-title":"NPJ Aging Mech Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"113863","DOI":"10.1016\/j.jviromet.2020.113863","article-title":"A Simple, Two-Step, Small-Scale Purification of Recombinant Adeno-Associated Viruses","volume":"281","author":"Chen SH","year":"2020","unstructured":"Chen SH, Papaneri A, Walker M, Scappini E, Keys RD, Martin NP: A Simple, Two-Step, Small-Scale Purification of Recombinant Adeno-Associated Viruses. J Virol Methods 2020, 281:113863.","journal-title":"J Virol Methods"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1038\/ncomms3550","article-title":"Imaging energy status in live cells with a fluorescent biosensor of the intracellular ATP-to-ADP ratio","volume":"4","author":"Tantama M","year":"2013","unstructured":"Tantama M, Martinez-Francois JR, Mongeon R, Yellen G: Imaging energy status in live cells with a fluorescent biosensor of the intracellular ATP-to-ADP ratio. Nat Commun 2013, 4:2550.","journal-title":"Nat Commun"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1126\/science.aad3358","article-title":"Cell-specific restoration of stimulus preference after monocular deprivation in the visual cortex","volume":"352","author":"Rose T","year":"2016","unstructured":"Rose T, Jaepel J, Hubener M, Bonhoeffer T: Cell-specific restoration of stimulus preference after monocular deprivation in the visual cortex. Science 2016, 352:1319\u20131322.","journal-title":"Science"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/s41592-020-00981-9","article-title":"Next-generation GRAB sensors for monitoring dopaminergic activity in vivo","volume":"17","author":"Sun F","year":"2020","unstructured":"Sun F, Zhou J, Dai B, Qian T, Zeng J, Li X, Zhuo Y, Zhang Y, Wang Y, Qian C, et al: Next-generation GRAB sensors for monitoring dopaminergic activity in vivo. Nat Methods 2020, 17:1156\u20131166.","journal-title":"Nat Methods"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nmeth.2836","article-title":"Independent optical excitation of distinct neural populations","volume":"11","author":"Klapoetke NC","year":"2014","unstructured":"Klapoetke NC, Murata Y, Kim SS, Pulver SR, Birdsey-Benson A, Cho YK, Morimoto TK, Chuong AS, Carpenter EJ, Tian Z, et al: Independent optical excitation of distinct neural populations. Nat Methods 2014, 11:338\u2013346.","journal-title":"Nat Methods"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.neuron.2018.04.012","article-title":"Spectrally Resolved Fiber Photometry for Multi-component Analysis of Brain Circuits","volume":"98","author":"Meng C","year":"2018","unstructured":"Meng C, Zhou J, Papaneri A, Peddada T, Xu K, Cui G: Spectrally Resolved Fiber Photometry for Multi-component Analysis of Brain Circuits. Neuron 2018, 98:707\u2013717 e704.","journal-title":"Neuron"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"e587","DOI":"10.1002\/cpz1.587","article-title":"Spectrally Resolved Fiber Photometry for In Vivo Multi-Color Fluorescence Measurements","volume":"2","author":"Zhou J","year":"2022","unstructured":"Zhou J, Yeh A, Meng C, Papaneri AB, Peddada T, Kobzar NP, Cui G: Spectrally Resolved Fiber Photometry for In Vivo Multi-Color Fluorescence Measurements. Curr Protoc 2022, 2:e587.","journal-title":"Curr Protoc"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1172\/JCI72176","article-title":"Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation","volume":"124","author":"Liu G","year":"2014","unstructured":"Liu G, Yu J, Ding J, Xie C, Sun L, Rudenko I, Zheng W, Sastry N, Luo J, Rudow G, Troncoso JC, Cai H: Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation. The Journal of clinical investigation 2014, 124:3032\u20133046.","journal-title":"The Journal of clinical investigation"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00702-019-02106-9","article-title":"The catecholaldehyde hypothesis: where MAO fits in","volume":"127","author":"Goldstein DS","year":"2020","unstructured":"Goldstein DS: The catecholaldehyde hypothesis: where MAO fits in. J Neural Transm (Vienna) 2020, 127:169\u2013177.","journal-title":"J Neural Transm (Vienna)"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/2047-9158-3-27","article-title":"Aldehyde Dehydrogenase 1 making molecular inroads into the differential vulnerability of nigrostriatal dopaminergic neuron subtypes in Parkinson's disease","volume":"3","author":"Cai H","year":"2014","unstructured":"Cai H, Liu G, Sun L, Ding J: Aldehyde Dehydrogenase 1 making molecular inroads into the differential vulnerability of nigrostriatal dopaminergic neuron subtypes in Parkinson's disease. Transl Neurodegener 2014, 3:27.","journal-title":"Transl Neurodegener"},{"key":"ref42","first-page":"E1876-E1885","article-title":"NAD(+) supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency","volume":"115","author":"Hou Y","year":"2018","unstructured":"Hou Y, Lautrup S, Cordonnier S, Wang Y, Croteau DL, Zavala E, Zhang Y, Moritoh K, O'Connell JF, Baptiste BA, et al: NAD(+) supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc Natl Acad Sci U S A 2018, 115:E1876-E1885.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"12948","DOI":"10.1038\/ncomms12948","article-title":"Nicotinamide riboside is uniquely and orally bioavailable in mice and humans","volume":"7","author":"Trammell SA","year":"2016","unstructured":"Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME, Brenner C: Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun 2016, 7:12948.","journal-title":"Nat Commun"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"644776","DOI":"10.3389\/fncir.2021.644776","article-title":"Function and Regulation of ALDH1A1-Positive Nigrostriatal Dopaminergic Neurons in Motor Control and Parkinson's Disease","volume":"15","author":"Carmichael K","year":"2021","unstructured":"Carmichael K, Evans RC, Lopez E, Sun L, Kumar M, Ding J, Khaliq ZM, Cai H: Function and Regulation of ALDH1A1-Positive Nigrostriatal Dopaminergic Neurons in Motor Control and Parkinson's Disease. Front Neural Circuits 2021, 15:644776.","journal-title":"Front Neural Circuits"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.conb.2016.02.005","article-title":"The basal ganglia: from motor commands to the control of vigor","volume":"37","author":"Dudman JT","year":"2016","unstructured":"Dudman JT, Krakauer JW: The basal ganglia: from motor commands to the control of vigor. Curr Opin Neurobiol 2016, 37:158\u2013166.","journal-title":"Curr Opin Neurobiol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1038\/s41467-025-58007-x","article-title":"Molecularly distinct striatonigral neuron subtypes differentially regulate locomotion","volume":"16","author":"Dong J","year":"2025","unstructured":"Dong J, Wang L, Sullivan BT, Sun L, Martinez Smith VM, Chang L, Ding J, Le W, Gerfen CR, Cai H: Molecularly distinct striatonigral neuron subtypes differentially regulate locomotion. Nat Commun 2025, 16:2710.","journal-title":"Nat Commun"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"7917","DOI":"10.1523\/JNEUROSCI.5298-09.2010","article-title":"Vesicular monoamine and glutamate transporters select distinct synaptic vesicle recycling pathways","volume":"30","author":"Onoa B","year":"2010","unstructured":"Onoa B, Li H, Gagnon-Bartsch JA, Elias LA, Edwards RH: Vesicular monoamine and glutamate transporters select distinct synaptic vesicle recycling pathways. The Journal of neuroscience: the official journal of the Society for Neuroscience 2010, 30:7917\u20137927.","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuron.2009.12.023","article-title":"Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis","volume":"65","author":"Nemani VM","year":"2010","unstructured":"Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RH: Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010, 65:66\u201379.","journal-title":"Neuron"},{"key":"ref49","first-page":"205","article-title":"The Na-K-ATPase and calcium-signaling microdomains","volume":"23","author":"Tian J","year":"2008","unstructured":"Tian J, Xie ZJ: The Na-K-ATPase and calcium-signaling microdomains. Physiology (Bethesda) 2008, 23:205\u2013211.","journal-title":"Physiology (Bethesda)"},{"key":"ref50","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a005637","article-title":"Synaptic vesicle exocytosis","volume":"3","author":"Sudhof TC","year":"2011","unstructured":"Sudhof TC, Rizo J: Synaptic vesicle exocytosis. Cold Spring Harb Perspect Biol 2011, 3.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.cub.2015.07.050","article-title":"Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons","volume":"25","author":"Pacelli C","year":"2015","unstructured":"Pacelli C, Giguere N, Bourque MJ, Levesque M, Slack RS, Trudeau LE: Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons. Curr Biol 2015, 25:2349\u20132360.","journal-title":"Curr Biol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"10736","DOI":"10.1074\/jbc.R112.410530","article-title":"Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease","volume":"288","author":"Surmeier DJ","year":"2013","unstructured":"Surmeier DJ, Schumacker PT: Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease. The Journal of biological chemistry 2013, 288:10736\u201310741.","journal-title":"The Journal of biological chemistry"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/mds.25095","article-title":"Neuronal vulnerability, pathogenesis, and Parkinson's disease","volume":"28","author":"Sulzer D","year":"2013","unstructured":"Sulzer D, Surmeier DJ: Neuronal vulnerability, pathogenesis, and Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society 2013, 28:41\u201350.","journal-title":"Movement disorders: official journal of the Movement Disorder Society"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9970859\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9970859\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:01:43Z","timestamp":1781884903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9970859\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":53,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9970859\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,6,19]]},"subtype":"preprint"}}